Patient perspectives of atopic dermatitis: comparative analysis of terminology in social media and scientific literature, identified by a systematic literature review

Autor: J.I. Silverberg, S.R. Feldman, W. Smith Begolka, M.B. Johnson, C. Stanojev, M. DiBonaventura, R. Rojo Cella, H. Valdez, C. Feeney, J.P. Thyssen

Publikováno v: Silverberg, J I, Feldman, S R, Smith Begolka, W, Johnson, M B, Stanojev, C, Dibonaventura, M, Rojo Cella, R, Valdez, H, Feeney, C & Thyssen, J P 2022, ' Patient perspectives of atopic dermatitis: comparative analysis of terminology in social media and scientific literature, identified by a systematic literature review ', Journal of the European Academy of Dermatology and Venereology, vol. 36, no. 11, pp. 1980-1990 . https://doi.org/10.1111/jdv.18442

Atopic dermatitis (AD) is a chronic skin disease that significantly impacts patient quality of life (QoL). It is unknown whether patients and physicians have the same interpretation of AD burden. Unmet needs and AD disease burden were evaluated by co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d2c5bc24460139df477fd0070bd711c
https://curis.ku.dk/portal/da/publications/patient-perspectives-of-atopic-dermatitis-comparative-analysis-of-terminology-in-social-media-and-scientific-literature-identified-by-a-systematic-literature-review(2c90772a-ee0c-46d3-952e-5d9e01ca2625).html

High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits:pooled analyses of abrocitinib monotherapy studies in adults and adolescents

Autor: S. Ständer, N. Bhatia, M. J. Gooderham, J. I. Silverberg, J. P. Thyssen, P. Biswas, M. DiBonaventura, W. Romero, S. A. Farooqui

Publikováno v: Stander, S, Bhatia, N, Gooderham, M J, Silverberg, J, Thyssen, J P, Biswas, P, DiBonaventura, M, Romero, W & Farooqui, S A 2022, ' High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits : pooled analyses of abrocitinib monotherapy studies in adults and adolescents ', Journal of the European Academy of Dermatology and Venereology, vol. 36, no. 8, pp. 1308-1317 . https://doi.org/10.1111/jdv.18170

Once-daily abrocitinib treatment provided meaningful improvements in signs and symptoms of moderate-to-severe atopic dermatitis (AD) in randomized controlled studies.To evaluate proportions of patients with responses meeting higher threshold efficacy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d026512c5f37c6345f908a31063dea49
https://curis.ku.dk/portal/da/publications/high-threshold-efficacy-responses-in-moderatetosevere-atopic-dermatitis-are-associated-with-additional-quality-of-life-benefits(2871bc48-86c0-4ded-bf46-79a96d3e45e7).html

P29 Comparing G-Computation, Propensity Score-Based Weighting, and Targeted Maximum Likelihood Estimation for Analyzing Externally Controlled Trials with an Unmeasured Confounder: A Simulation Study

Autor: J. Ren, P. Cislo, JC. Cappelleri, P. Hlavacek, M. DiBonaventura

Publikováno v: Value in Health. 25:S293

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5625b01aaed0b50d7195a758945118dd
https://doi.org/10.1016/j.jval.2022.04.039

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.